Palvella Therapeutics completed a Phase 3 trial for QTORIN™ rapamycin, targeting a rare genetic disease, with results expected in 2026. Top-line results from the SELVA trial are expected in the first ...

Aging-US is dedicated to advancing our understanding of the biological mechanisms that drive aging and the development of age-related diseases. Our mission is to serve as a platform for high-quality ...

Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025 Venous malformations are the most common ...

Researchers at the University of Arizona R. Ken Coit College of Pharmacy will begin a double-blind, randomized Phase 3 clinical trial during 2026 to evaluate whether a drug used to prevent organ ...

WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel ...

For centuries, humans have searched for ways to extend life. Alchemists never found the philosopher's stone, but scientists have consistently shown that a longer life can be attained by eating less—at ...

FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submitted ...

The longevity and bio-hacking sector of medicine is known to be highly experimental, with a lot being pushed by fitness and health influencers that still requires significant testing. Also Read | ...

Add Yahoo as a preferred source to see more of our stories on Google. Rapamycin has been hyped as a longevity breakthrough and even the fountain of youth, but new research says the excitement is ...

The anti-aging drug rapamycin has the same life-extending effect as eating less, according to new research from the University of East Anglia and University of Glasgow. Dietary restriction has long ...